Agenus | AGEN - Net Income


Agenus reported $-10.63M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Celldex Therapeutics USD -78.68M 2.63M Mar/2026
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
J&J USD 5.24B 119M Mar/2026
Jiangsu Hengrui CNY 2.28B 322.38M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck EUR 659M 340M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Northwest Biotherapeutics USD -27.18M 7.81M Sep/2025
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 28.71M 12.44M Mar/2026